Insider buying last 90 days
No open-market insider purchases were filed for ABBV in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ABBV insider filing, plotted on the chart in Gekko.Open ABBV in Gekko
NYSE: ABBV
AbbVie (ABBV) Stock Analysis & Forecast
Nov 4 close
$294.83+8.83 (+3.1%)
Gekko Brief
AI summaryNov 4 closeAbbVie's week was shaped by a flurry of dealmaking and R&D news. The company struck a licensing agreement with Nxera Pharma for NXE0033744, an EP4 receptor agonist for inflammatory bowel disease, in a deal described as worth up to $1.5 billion, with an upfront cash payment of $100 million and potential milestones reported variously up to $1.47 billion and $1.37 billion. AbbVie also announced an expansion of its Oxford, UK research facility with an investment of over £120 million ($161 million), adding a 12,000-square-foot site focused on immunology, neuroscience and oncology. This follows last week's Q3 2026 results, which showed adjusted EPS of $3.82 against a $3.73 estimate, with total net revenues of $17.4 billion.
AbbVie last closed at $294.83, up 3.1%, sitting above both its 50-day average of $270.78 and its 200-day average of $238.22. The stock's one-month return stands at 10.6%, with a three-month return of 20.9% and a six-month return of 43.8%. The GekkoIndex reads 45.6, placing it in the Neutral zone, down 2.3 over five days. Gekko Fair Value is set at $233.07, putting the current price 26.5% above that level.
Looking ahead, the next earnings date falls on 3 February 2027, 90 days out and beyond a typical 20-day holding window. No insider, Congress or unusual options activity appears in the recent windows. Analyst consensus from 24 firms shows 20 buy ratings, 4 hold and a consensus target of $305.58. Seasonally, the next 20 trading days have averaged a 2.7% gain over 5 years, rising in 4 of them — a pattern worth noting alongside the current gap to fair value.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
AbbVie price vs fair value
Close $294.83200-day averageGekko Fair Value $233.07
AbbVie quick facts
- Market cap
- $521.0B
- P/E ratio
- 50.7
- Forward P/E
- 18.2
- EPS, TTM
- $5.70
- Revenue, TTM
- $66.01B
- Profit margin
- 15.7%
- Dividend yield
- 2.35%
- Beta
- 0.19
- Volume
- 8.40M avg 5.36M
- 1-year return
- +39.1%
- Typical daily move
- ±2.3%
- Typical 20-day move
- ±4.7%
- 50-day average
- $270.78
- 200-day average
- $238.22
- Next earnings
- Feb 3 before open
- Shares outstanding
- 1.77B
AbbVie swing-trade checklist
AbbVie scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $294.83 is above the 50-day ($270.78) and 200-day ($238.22) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
45.6, Neutral
Reading 45.6 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
26.5% above
Price is 26.5% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 90 days
Next report Feb 3, 2027, 90 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.7% on average
From this point in the calendar, the next 20 trading days averaged +2.7% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
AbbVie stock chart and price history
AbbVie closed at $294.83 on Nov 4, 2026, +39.1% over the past year, inside a 52-week range of $190.75 to $298.74.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +10.6%
- 3 months
- +20.9%
- 6 months
- +43.8%
- 1 year
- +39.1%
The full ABBV chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ABBV in Gekko
Follow AbbVie through every session
Put ABBV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ABBV in GekkoFree for 7 days. No credit card required.
About AbbVie
AbbVie develops and manufactures medicines across a wide range of treatment areas, including immunology, cancer care, liver disease, digestive and hormonal conditions, women's health, neurology, and eye care. It is widely recognized for immunology treatments such as Humira, Skyrizi, and Rinvoq, along with cancer drugs like Imbruvica and Venclexta for certain blood cancers. Other products address conditions ranging from hepatitis C and pancreatic enzyme deficiency to migraines, Parkinson's disease, and glaucoma, and its lineup also includes the therapeutic form of Botox.
Its business spans several specialty areas rather than a single product line, supplying treatments to patients with chronic and often serious conditions such as autoimmune disorders, endometriosis, prostate cancer, and thyroid deficiency. Beyond its own drug portfolio, AbbVie takes part in outside research partnerships, including work with Dragonfly Therapeutics, to support further drug development.
AbbVie was founded in 2012 and is headquartered in North Chicago, Illinois. Its shares are listed on the NYSE under the ticker ABBV.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- abbvie.com
AbbVie GekkoIndex: the smart money zone
AbbVie’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45.6, in the Neutral zone, down 2.3 points over five sessions.
45.6Neutral
Down 2.3 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 19 | +2.2% | +2.3% | ||
| Accumulation | 170 | +1.0% | +1.7% | ||
| Neutral (current zone) | 440 | +0.2% | +1.7% | ||
| Distribution | 62 | +0.6% | +1.3% | ||
| Selling | 6 | Too few readings yet | |||
Average ABBV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ABBV price, zone by zone.Track ABBV in Gekko
Is AbbVie stock overvalued? Gekko Fair Value
AbbVie trades 26.5% above Gekko Fair Value of $233.07, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what AbbVie shares are worth, recalculated every trading day.
$233.07
Gekko Fair Value, Nov 4, 2026
26.5% Overvalued
At the end of Aug 2026 the price was 19.4% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ABBV in Gekko
AbbVie insider and Congress trading
No open-market insider purchases were filed for AbbVie, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ABBV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ABBV, plotted on the chart in Gekko.Open ABBV in Gekko
Buybacks
AbbVie has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $9.00M
- As a share of market cap
- 0.00%
- Trailing four quarters
- $1.51B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ABBV.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
AbbVie earnings: next date and track record
AbbVie reports on Feb 3, 2027, before the open (90 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Feb 3, 2027
Expected before the open, 90 days away
- EPS estimate
- $3.90
- Revenue estimate
- $18.33B
5 of 8reports beat the EPS estimate
±5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 30, 2026 AI summary
- What they said
- AbbVie reported Q3 2026 adjusted EPS of $3.82, beating guidance by $0.07, with total net revenues of $17.4 billion, up 10%+ year-over-year. Immunology revenues approached $9.2 billion (+16.6%), driven by Skyrizi ($5.8 billion, +22.9%) and Rinvoq. Nine products delivered double-digit growth. Pipeline advances include Apogee Therapeutics acquisition, FDA approvals for Skyrizi subcu induction and Juvmo, and etentamig submission for multiple myeloma.
- Guidance
- AbbVie raised full-year revenue guidance by $200 million, totaling $800 million in increases since year-start. Management announced a 5.2% quarterly dividend increase. Parkinson's therapies projected to reach $5 billion+ peak sales; etentamig approval anticipated in 2027.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 30, 2026 | $3.82 est $3.73 | $17.40B est $17.32B | −0.7% |
| Jul 31, 2026 | $3.65 est $3.64 | $16.99B est $16.80B | −4.8% |
| Apr 29, 2026 | $2.65 est $2.67 | $15.00B est $14.72B | +6.9% |
| Feb 4, 2026 | $2.71 est $3.35 | $16.62B est $16.41B | −2.9% |
| Oct 31, 2025 | $1.86 est $1.77 | $15.78B est $15.59B | −7.1% |
| Jul 31, 2025 | $2.97 est $2.88 | $15.42B est $15.03B | +3.1% |
| Apr 25, 2025 | $2.46 est $2.38 | $13.34B est $12.93B | +6.6% |
| Jan 31, 2025 | $2.16 est $2.98 | $15.10B est $14.83B | +8.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
AbbVie stock forecast and analyst price targets
Analysts’ average 12-month price target for AbbVie is $305.58, +3.6% from the last close, from 24 firms rating the stock in the last 90 days.
$305.58consensus 12-month target, +3.6% from the last close
Now $294.83Avg $305.58
Low $230High $346
Each firm’s latest rating in the last 90 days: 24 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 4 | Freedom Capital Markets | $315 | +6.8% |
| Nov 2 | Goldman Sachs | $313 | +6.2% |
| Nov 2 | UBS | $295 | +0.1% |
| Nov 2 | Morgan Stanley | $346 | +17.4% |
| Nov 2 | BMO Capital | $340 | +15.3% |
+1.7%average 20-day move after past Neutral readings
+2.7%average move over the next 20 trading days in the last 5 years
±2.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
AbbVie seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, AbbVie averaged +2.7% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.5% | 2 of 5 |
| Next 10 trading days | −0.8% | 3 of 5 |
| Next 15 trading days | +0.5% | 2 of 5 |
| Next 20 trading days | +2.7% | 4 of 5 |
| Next 30 trading days | +4.3% | 4 of 5 |
For scale, ABBV’s typical 20-trading-day move in either direction is about 4.7%.
AbbVie market cap and key statistics
AbbVie’s market cap is $521.0B, with a P/E ratio of 50.7 and revenue of $66.01B over the last twelve months.
Valuation
- Market cap
- $521.0B
- P/E ratio
- 50.7
- Forward P/E
- 18.2
- EPS, TTM
- $5.70
- Gekko Fair Value
- $233.07
Trading
- Volume
- 8.40M
- Avg volume, 20 days
- 5.36M
- 52-week high
- $298.74
- 52-week low
- $190.75
- Shares outstanding
- 1.77B
Financials
- Revenue, TTM
- $66.01B
- Profit margin
- 15.7%
- Return on equity
- 62.3%
- Quarterly earnings growth, YoY
- +2,282.0%
Risk and income
- Beta
- 0.19
- Typical daily move
- ±2.3%
- Typical 20-day move
- ±4.7%
- Dividend yield
- 2.35%
AbbVie stock news this week
Coverage of AbbVie this week reads positive: 16 positive, 3 neutral and 1 negative headlines.
- AbbVie bets up to $1.47B for Nxera’s discarded IBD programBioSpace, Nov 4
- Roundup: Boehringer Ingelheim Licenses Six Oncology Programs From Sino Biopharmaceutical, Nxera Licenses EP4 Agonist to AbbViePharmaceutical Executive, Nov 4
- AbbVie, Nxera ink licensing deal worth up to $1.5B for bowel disease therapySeeking Alpha, Nov 4
- AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with NxeraPharmaceutical Technology, Nov 4
- AbbVie’s Oxford R&D Expansion Is Welcome News For UKScrip, Nov 4
- Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?Zacks Investment Research, Nov 4
AbbVie peers
AbbVie’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| JNJJohnson & Johnson | Neutral | 1.7% below |
| MRKMerck | Neutral | 8.6% below |
| AZNAstraZeneca | Distribution | 34.1% below |
| PFEPfizer | Neutral | 4.1% below |
| VRTXVertex Pharmaceuticals | Neutral | 16.8% above |
A peer links to its own page where one exists.
AbbVie stock FAQ
What is AbbVie’s market cap?
AbbVie’s market cap is $521.0B at the Nov 4, 2026 close of $294.83, with 1.77B shares outstanding. The shares trade on a P/E ratio of 50.7.
What is the AbbVie stock forecast?
The consensus analyst 12-month price target for AbbVie is $305.58, +3.6% from the last close. Of the 24 firms that rated the stock in the last 90 days, 20 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is AbbVie stock overvalued or undervalued?
On Gekko’s estimate AbbVie is overvalued: the Nov 4, 2026 close of $294.83 is 26.5% above Gekko Fair Value of $233.07. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does AbbVie report earnings next?
AbbVie is expected to report on Feb 3, 2027, before the market opens (90 days away). Analysts expect earnings of $3.90 per share on revenue of $18.33B. AbbVie beat the earnings estimate in 5 of its last 8 reports, moving 5% on average across the report.
What is AbbVie’s 52-week high and low?
AbbVie’s 52-week high is $298.74 and its 52-week low is $190.75; it closed at $294.83 on Nov 4, 2026, +39.1% over the past year.
Is AbbVie stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See AbbVie the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.